October 17, 2019 10:32 AM EDT

After 13% discount Innate Pharma raises $69M; AZTherapies bags $26.3M from Series C financing round

Kathy Wong

Editor

→ AstraZeneca-partnered French biotech Innate Pharma — which was shooting for a $100 million IPO by offering 10.7 millions shares at $7.50 per share …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

After 13% discount Innate Pharma raises $69M; AZTherapies bags $26.3M from Series C financing round

Kathy Wong

Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA approves first drug to treat ultra-rare lipid storage disease

Will CRISPR matter?

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Af­ter 13% dis­count In­nate Phar­ma rais­es $69M; AZTher­a­pies bags $26.3M from Se­ries C fi­nanc­ing round

Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

After 13% discount Innate Pharma raises $69M; AZTherapies bags $26.3M from Series C financing round